Skip to main content
UniHealth

Doctor search

Michael Alexander Spinner, MD

Hematology/Oncology · Berkeley

NPI 1639589567

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Offices
5

Offices

5 locations · UCSF Medical Group Business Services · University of California San Francisco · Regents of the University of California

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Spinner’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

California Medical Board record

Licence A140983 · Current

Licensed to practise in California · since 2016 · expires 2027-12-31 · Vanderbilt University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$61,998

Medicare paid this office $61,998 for 172 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)107$34,242$125
New patient visit (60+ min)47$6,366$135
Return visit (30+ min)52$5,632$72
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's137$3,910$15

Who their Medicare patients are

172 Original Medicare patients in 2024. Average age 73 · Under 65 8% · 85 and older 8% · Women 48% · Also on Medicaid 21% · Health risk score 2.26. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 55% · Chronic kidney disease 22% · Atrial fibrillation 21% · Coronary heart disease 20% · Cancer 19% · Depression 18% · Diabetes 14% · COPD 13% · Heart failure 10%.

The office billed $509,290, Medicare allowed $82,117 and paid $61,998; for 980 services of 23 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024172980732.26$509,290$61,998
2023150430732.31$359,211$47,854
202299237731.80$195,258$27,250
20214889731.81$11,640$5,905

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Original Medicare services billed in 2023
Long return visit (40+ min)94$29,849$124
New patient visit (60+ min)48$7,781$162
Return visit (30+ min)31$3,285$84
Biopsy and aspiration of bone marrow sample for diagnosis12$826$69

2022: 3 services

Original Medicare services billed in 2022
Long return visit (40+ min)37$13,141$130
New patient visit (60+ min)55$8,942$163
Return visit (30+ min)16$1,503$68

2021: 2 services

Original Medicare services billed in 2021
Short return visit (20+ min)37$3,326$55
Return visit (30+ min)16$2,083$91

Medicaid work

$6,815 in 2024

Medicaid paid $6,815 for 51 billed services this clinician did in 2024, up to 16 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)51$6,815
Medicaid work by year
202451116$6,815
202313112$1,551
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)13$1,551

Drugs they prescribed that Part D paid

$2,601,158

Pharmacies billed $2,601,158 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

300 generic and fewer than 11 brand-name prescriptions · $2,601,158 in drug cost · 38 antibiotic prescriptions to 15 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Brukinsa142$1,681,889$11,844
Calquence33$459,983$13,939
Xarelto13$8,597$661
Entecavir23$7,240$315
Acyclovir83$1,304$16
See all 10 drugs
Every Part D drug this clinician prescribed
Brukinsa142$1,681,889$11,844
Calquence33$459,983$13,939
Xarelto13$8,597$661
Entecavir23$7,240$315
Acyclovir83$1,304$16
Ondansetron33$216$7
Prochlorperazine Maleate11$118$11
Prednisone23$95$4
Allopurinol12$78$7
Sulfamethoxazole-Trimethoprim25$58$2

Year by year

Part D prescribing by year
202453578NoneNone$2,601,158
202333357NoneNone$1,774,131
202221447NoneNone$431,046
202124635None14%$307,184
2020102160% (0)19%$202,268
201954None0% (0)20%$141,997

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 8 drugs

Part D drugs prescribed in 2023
Brukinsa63$842,365$13,371
Calquence38$548,389$14,431
Entecavir13$4,536$349
Acyclovir50$1,286$26
Ondansetron26$365$14
Prochlorperazine Maleate15$201$13
Allopurinol17$111$7
Prednisone14$86$6

2022: 7 drugs

Part D drugs prescribed in 2022
Valacyclovir11$998$91
Acyclovir17$335$20
Ondansetron20$307$15
Famotidine16$218$14
Prochlorperazine Maleate11$186$17
Prednisone20$150$7
Allopurinol11$103$9

2021: 8 drugs

Part D drugs prescribed in 2021
Brukinsa16$229,333$14,333
Valacyclovir13$1,642$126
Ondansetron33$748$23
Famotidine45$679$15
Prednisone29$287$10
Prochlorperazine Maleate22$270$12
Allopurinol20$178$9
Lorazepam21$119$6

2020: 3 drugs

Part D drugs prescribed in 2020
Imbruvica14$183,090$13,078
Ondansetron13$197$15
Prednisone11$43$4

Money from drug and device companies

$6,208 in 2025

Industry payments by year
2025615$5,430$6,208
202412None$45
202349$4,470$5,651
202212None$173
201911None$125

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
PfizerAdcetris$3,969
5 payments
  • Meals for Adcetris · 2025-09-05 · $114
  • Consulting for Adcetris · 2025-07-02 · $1,860
  • Consulting for Adcetris · 2025-06-24 · $1,860
  • Meals for Talzenna · 2025-06-17 · $75
  • Meals for Adcetris · 2025-01-31 · $60
E.R. Squibb & Sons L.L.C.None$1,710
2 payments
  • Consulting · 2025-09-11 · $855
  • Consulting · 2025-08-21 · $855
One LambdaNone$319
4 payments
  • Meals · 2025-08-15 · $78
  • Meals · 2025-08-05 · $43
  • Meals · 2025-08-05 · $146
  • Meals · 2025-08-02 · $52
AbbvieEpkinly$128
2 payments
  • Meals for Epkinly · 2025-08-27 · $108
  • Meals for Imbruvica · 2025-01-30 · $21
CelgeneBreyanzi$42
1 payment
  • Meals for Breyanzi · 2025-06-18 · $42
Adaptive BiotechnologiesClonoseq$41
1 payment
  • Meals for Clonoseq · 2025-09-03 · $41
See all 15 published payments
Every published payment
E.R. Squibb & Sons L.L.C.Consulting · 2025-09-11None$855
PfizerMeals · 2025-09-05Adcetris$114
Adaptive BiotechnologiesMeals · 2025-09-03Clonoseq$41
AbbvieMeals · 2025-08-27Epkinly$108
E.R. Squibb & Sons L.L.C.Consulting · 2025-08-21None$855
One LambdaMeals · 2025-08-15None$78
One LambdaMeals · 2025-08-05None$43
One LambdaMeals · 2025-08-05None$146
One LambdaMeals · 2025-08-02None$52
PfizerConsulting · 2025-07-02Adcetris$1,860
PfizerConsulting · 2025-06-24Adcetris$1,860
CelgeneMeals · 2025-06-18Breyanzi$42
PfizerMeals · 2025-06-17Talzenna$75
PfizerMeals · 2025-01-31Adcetris$60
AbbvieMeals · 2025-01-30Imbruvica$21
See earlier years (2024, 2023, 2022, 2019)

2024: $45

Payments by company in 2024
AbbvieImbruvica$45
2 payments
  • Meals for Imbruvica · 2024-10-04 · $20
  • Meals for Imbruvica · 2024-05-14 · $25

2023: $5,651

Payments by company in 2023
Kite PharmaYescarta$4,369
5 payments
  • Consulting for Yescarta · 2023-02-10 · $3,270
  • Meals for Yescarta · 2023-01-24 · $9
  • Travel for Yescarta · 2023-01-24 · $283
  • Travel for Yescarta · 2023-01-24 · $372
  • Travel for Yescarta · 2023-01-24 · $435
ADC Therapeutics AmericaNone$1,200
1 payment
  • Consulting · 2023-05-03 · $1,200
Pharmacyclics LLC An AbbVieImbruvica$47
2 payments
  • Meals for Imbruvica · 2023-10-25 · $17
  • Meals for Imbruvica · 2023-05-18 · $30
Janssen BiotechTecvayli$36
1 payment
  • Meals for Tecvayli · 2023-12-09 · $36

2022: $173

Payments by company in 2022
SeagenNone$173
2 payments
  • Meals · 2022-12-10 · $73
  • Meals · 2022-08-18 · $99

2019: $125

Payments by company in 2019
Seattle GeneticsAdcetris$125
1 payment
  • Meals for Adcetris · 2019-02-28 · $125

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
PFIZER INC. · A Phase 1 Openlabel Study To Evaluate Sgn35c in Adults With Advanced Malignancies · 2025Their institution$300,205
PFIZER INC. · A Phase 1 Openlabel Study To Evaluate Sgn35c in Adults With Advanced Malignancies · 2024Their institution$49,569
Eli Lilly and Company · A Phase 1 Study of Oral Loxo-338, A Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies · 2022Their institution$32,490
Eli Lilly and Company · A Phase 1 Study of Oral Loxo-338 A Selective Bcl-2 Inhibitor in Patients With Advanced Hematologic Malignancies · 2023Their institution$6,467
PFIZER INC. · Ladiratuzumab Vedotin Clinical Publication Program · 2025This clinician$940
PFIZER INC. · Pf06647263 Clinical Publication Program · 2024This clinician$330
PFIZER INC. · Elranatamab Clinical Publication Program · 2025This clinician$330

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
74.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1639589567
Licence
CA A140983California A140983: Current · expires 2027-12-31
Trained
Vanderbilt University School of Medicine, 2014
Group
UCSF Medical Group Business Services · University of California San Francisco · Regents of the University of California
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Medical oncology (207RX0202X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2014-04-30
NPI last updated
2020-07-09
NPI record certified
2020-07-09

This is when the NPI record was last certified, not a medical board exam.